Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.681,09
-0,07%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Verve Therapeutics Inc (VERV) Verve Therapeutics Inc (VERV) Notizie

VERV

Verve Therapeutics (VERV)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VERV
DataOraFonteTitoloSimboloCompagnia
31/05/202422:01GlobeNewswire Inc.Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VERVVerve Therapeutics Inc
31/05/202413:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VERVVerve Therapeutics Inc
31/05/202413:00GlobeNewswire Inc.Verve Therapeutics Announces Leadership UpdateNASDAQ:VERVVerve Therapeutics Inc
30/05/202422:01GlobeNewswire Inc.Verve Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:VERVVerve Therapeutics Inc
08/05/202413:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VERVVerve Therapeutics Inc
08/05/202413:00GlobeNewswire Inc.Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial ResultsNASDAQ:VERVVerve Therapeutics Inc
07/05/202413:00GlobeNewswire Inc.Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102NASDAQ:VERVVerve Therapeutics Inc
02/04/202413:00GlobeNewswire Inc.Verve Therapeutics Announces Updates on its PCSK9 ProgramNASDAQ:VERVVerve Therapeutics Inc
27/02/202414:32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VERVVerve Therapeutics Inc
27/02/202414:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VERVVerve Therapeutics Inc
27/02/202413:30GlobeNewswire Inc.Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VERVVerve Therapeutics Inc
16/02/202422:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VERVVerve Therapeutics Inc
01/02/202412:30GlobeNewswire Inc.Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:VERVVerve Therapeutics Inc
02/01/202412:30GlobeNewswire Inc.Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VERVVerve Therapeutics Inc
01/12/202322:00GlobeNewswire Inc.Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private PlacementNASDAQ:VERVVerve Therapeutics Inc
29/11/202322:47Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VERVVerve Therapeutics Inc
29/11/202312:47Dow Jones NewsVerve Therapeutics Shares Tumble Premarket After Stock SalesNASDAQ:VERVVerve Therapeutics Inc
29/11/202304:37GlobeNewswire Inc.Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private PlacementNASDAQ:VERVVerve Therapeutics Inc
28/11/202322:01GlobeNewswire Inc.Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private PlacementNASDAQ:VERVVerve Therapeutics Inc
12/11/202321:30GlobeNewswire Inc.Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial HypercholesterolemiaNASDAQ:VERVVerve Therapeutics Inc
07/11/202312:30GlobeNewswire Inc.Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial ResultsNASDAQ:VERVVerve Therapeutics Inc
31/10/202311:59Dow Jones NewsBeam Therapeutics to Sell Rights in Verve Licensing Deal to Lilly for $250 Million UpfrontNASDAQ:VERVVerve Therapeutics Inc
31/10/202311:01GlobeNewswire Inc.Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3NASDAQ:VERVVerve Therapeutics Inc
23/10/202313:22Dow Jones NewsVerve Therapeutics Gets Clinical Hold For VERVE-101 Lifted By FDANASDAQ:VERVVerve Therapeutics Inc
23/10/202312:30GlobeNewswire Inc.Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial HypercholesterolemiaNASDAQ:VERVVerve Therapeutics Inc
26/09/202312:30GlobeNewswire Inc.Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023NASDAQ:VERVVerve Therapeutics Inc
21/09/202322:05GlobeNewswire Inc.Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare ConferenceNASDAQ:VERVVerve Therapeutics Inc
18/09/202312:30GlobeNewswire Inc.Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical OfficerNASDAQ:VERVVerve Therapeutics Inc
10/08/202312:30GlobeNewswire Inc.Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial ResultsNASDAQ:VERVVerve Therapeutics Inc
03/08/202312:30GlobeNewswire Inc.Verve Therapeutics to Present at the Canaccord 43rd Annual Growth ConferenceNASDAQ:VERVVerve Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VERV

La tua Cronologia

BIT
UCG
Unicredit
BIT
TIT
Telecom Italia
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
STMMI
ST Microelectronics
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TITR
Telecom Italia
BIT
ENEL
Enel
BIT
TEN
Tenaris
BIT
BPE
Bper Banca
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
PIRC
Pirelli & C
BIT
SPM
Saipem
BIT
MONC
Moncler
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network